| 1 |
34159337 | Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 replication, inflammation, and lung injury by a drug repurposing screen. | 2021 Jun 15 |
1 |
| 2 |
30590459 | Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors. | 2019 Aug 22 |
1 |
| 3 |
29271513 | Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer. | 2018 Jul |
2 |
| 4 |
28243326 | The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma. | 2017 |
2 |
| 5 |
28744398 | Kinase inhibitors of HER2/AKT pathway induce ERK phosphorylation via a FOXO-dependent feedback loop. | 2017 |
8 |
| 6 |
29113345 | Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems. | 2017 Oct 6 |
4 |
| 7 |
27708243 | JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells. | 2016 Nov 1 |
1 |
| 8 |
27756261 | Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways. | 2016 Oct 19 |
1 |
| 9 |
25596742 | Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2. | 2015 Feb 10 |
3 |
| 10 |
26296355 | Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas. | 2015 Dec 15 |
2 |
| 11 |
24249715 | Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor. | 2014 Jan |
1 |
| 12 |
25225290 | A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells. | 2014 Oct 31 |
1 |
| 13 |
23365119 | Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. | 2013 May |
2 |
| 14 |
24263233 | Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line. | 2013 Nov 22 |
1 |
| 15 |
22407832 | Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. | 2012 May 1 |
2 |
| 16 |
22821509 | The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. | 2012 Nov |
1 |
| 17 |
21252284 | Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. | 2011 Mar |
1 |
| 18 |
21464044 | The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. | 2011 May 15 |
1 |
| 19 |
20179222 | Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. | 2010 Mar 1 |
2 |
| 20 |
19853943 | Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. | 2009 Dec |
2 |
| 21 |
16452222 | Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. | 2006 Feb 1 |
1 |
| 22 |
14751502 | Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. | 2004 Feb 1 |
1 |